Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...

Immunocompromised patients undergoing hematopoietic stem cell transplants (HSCTs) who have a reported penicillin allergy should be evaluated as the allergy label limits access to preferred antibiotics ...

Adia Med, the medical division of Adia Nutrition Inc. (OTC Pink: ADIA), proudly announces its ongoing registration with the ...

Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

The Metachromatic Leukodystrophy Initiative (MLDi) critically responds to the findings of Zhang et al. on lentivirus-modified ...

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to ...

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...